For instance, Li et al. [15] reported high levels of MALAT1 in advanced CRC patients, correlating with poorer overall survival and reduced response to FOLFOX therapy containing leucovorin calcium, fluorouracil, and oxaliplatin [25]. The gene discussed is MALAT1; the disease is colorectal carcinoma.